Status:
COMPLETED
The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics
Lead Sponsor:
Aspireo Pharmaceuticals Limited
Conditions:
Acromegaly
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study is designed to assess the effect of the different continuous s.c. infusion treatments on the human growth hormone (hGH) levels in untreated acromegalic patients in comparison to a standard ...
Eligibility Criteria
Inclusion
- Men, women of non child-bearing potential, or women of child-bearing potential who either abstain from sexual intercourse, have a sterile partner or practice two medically approved, non-hormonal methods of contraception
- Diagnosis of acromegaly of pituitary origin
- Have an age-adjusted insulin-like growth factor type 1 (IGF-1) concentration ≥1.2 times the upper limit of normal range on at least one measurement in the 12 months prior to screening (Visit 1) AND a second raised value screening
- Have at least one random hGH level of ≥5 μg/L in the 12 months prior to screening AND a second raised value at screening
- Have given written informed consent
- Ability to comply with the requirements of the protocol for the study
Exclusion
- Previous specific treatment for acromegaly in the 12 months prior to screening, including somatostatin analogues (SSAs); surgery; radiotherapy and pegvisomant
- Treatment with dopamine agonists in the 3 months prior to screening
- Uncontrolled hypertension
- Type I diabetes mellitus, poorly-controlled type II diabetes mellitus (glycosylated haemoglobin \[HbA1c\] ≥7.5%) and patients requiring insulin treatment
- Gallstones or gravel that could cause biliary obstruction
- Hyperprolactinaemia
- Participation in a clinical study within 60 days prior to screening
- Receipt of blood, blood products or plasma derivatives 60 days prior to screening
- Body mass index (BMI) below 22 or above 37 kg/m2
- Pregnancy, lactation or use of any hormonal based contraceptives
- Concomitant intake of corticosteroids or levodopa
- A history of active alcohol abuse or drug addiction
- Positive viral serology screening result for hepatitis B surface antigen, antibodies to hepatitis C virus, or human immunodeficiency virus type 1 and 2
- Evidence or suspicion of tumour expansion
- Clinically significant abnormality in screening ECG in the opinion of the Investigator
- Any clinically significant abnormal in screening laboratory safety test (biochemistry, haematology and dipstick urinalysis) in the opinion of the Investigator
- Any disease which in the Investigator's opinion would exclude the patient from the study
Key Trial Info
Start Date :
November 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2016
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT02217800
Start Date
November 1 2013
End Date
May 1 2016
Last Update
February 15 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.